Characterizing and developing strategies for the treatment of community-acquired pneumonia at a community hospital

Canadian Respiratory Journal

Volumn 9, Issue 4, 2002, Pages 247-252

  Fok, Mark C ^a   Kanji, Zahra ^a   Mainra, Rajesh ^a   Boldt, Michael ^a  

^a VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Antibiotics; Community acquired pneumonia; Guidelines; Management strategies; Pneumonia severity index

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CEFACLOR; CEFALEXIN; CEFOTAXIME; CEFUROXIME; CEPHALOSPORIN; CLARITHROMYCIN; CLINDAMYCIN; DOXYCYCLINE; ERYTHROMYCIN; GATIFLOXACIN; LEVOFLOXACIN; MACROLIDE; METRONIDAZOLE; MOXIFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CANADA; COMMUNITY HOSPITAL; CONTROLLED STUDY; COST CONTROL; DISEASE SEVERITY; DRUG CHOICE; DRUG COST; FEMALE; HEALTH CARE COST; HOSPITAL ADMISSION; HOSPITAL BED; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MONOTHERAPY; PNEUMONIA; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM;

EID: 0036659782     PISSN: 11982241     EISSN: None     Source Type: Journal    
DOI: 10.1155/2002/697424     Document Type: Article

References (11)

1. Issues and controversies in respiratory medicine. Conference proceedings. Phoenix, Arizona, USA. November 20-23, 1997. Can Respir J 1999;6(Suppl A):5A-53A.
2. Introduction to Table V. Premature deaths, monthly mortality and monthly physician contacts - United States. MMWR Morbid Mortal Wkly Rep 1997;46:556-61.
3. Pinner RW, Teutsch SM, Simonsen L. Trends in infectious diseases and mortality in the United States. JAMA 1996;275:189-93.
4. Mandell LA, Marrie TJ, Grossman RF, et al. Canadian guidelines for the initial management of community acquired pneumonia. Clin Infect Dis 2000;31:383-421.
5. Bartlett JG, Dowell S, Mandell L, File T, Musher D, Fine M. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000;31:347-82.
6. Bartlett JG, Breiman RF, Mandell LA, File TM Jr. Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America. Clin Infect Dis 1998;26:811-38.
7. Mandell LA, Niederman MS. Antimicrobial treatment of community-acquired pneumonia in adults: a conference report. Canadian Community-Acquired Pneumonia Consensus Conference Group. Can J Infect Dis 1993;4:25-8.
8. Benenson R, Magalski A, Cavanaugh S, Williams E. Effects of a pneumonia clinical pathway on time to antibiotic treatment, length of stay, and mortality. Acad Emerg Med 1999;6:1243-8.
9. Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. JAMA 2000;283:749-55.
10. Feagan BG, Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK. Treatment and outcomes of community-acquired pneumonia at Canadian hospitals. CMAJ 2000;162:1415-20.
11. Ramirez JA, Vargas S, Gilbert WR, et al. Early switch from intravenous to oral antibiotics and early hospital discharge. Arch Intern Med 1999;159:2449-54.